Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.74 |
| ▸ | EGFR | P00533 | 3/20 | 0.74 |
| ▸ | JAK1 | P23458 | 3/20 | 0.74 |
| ▸ | JAK3 | P52333 | 3/20 | 0.74 |
| ▸ | JAK2 | O60674 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.74 |
| ▸ | PLK4 | O00444 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 2/20 | 0.74 |
| ▸ | STK16 | O75716 | 2/20 | 0.74 |
| ▸ | RET | P07949 | 2/20 | 0.74 |
| ▸ | FLT3 | P36888 | 2/20 | 0.74 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.74 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.74 |
| ▸ | MST1R | Q04912 | 2/20 | 0.74 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.74 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.74 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.74 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.74 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380946 | 0.94 | SYK (0.67) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL1197041 | 0.92 | SYK (0.65) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL2103919 | 0.90 | SYK (0.66) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL13007744 | 0.90 | SYK (0.60) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL2103278 | 0.89 | SYK (0.69) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL2102713 | 0.89 | SYK (0.66) | SYKEGFRJAK1JAK3JAK2 | |
| Hydrochloric Acid SCHEMBL2100858 | 0.89 | SYK (0.68) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL2102943 | 0.88 | SYK (0.62) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL2105664 | 0.87 | SYK (0.73) | SYKEGFRJAK1JAK3JAK2 | |
| SCHEMBL4002240 | 0.87 | SYK (0.61) | SYKEGFRJAK1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656372-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2013-04-10 | — | — | EP | claimed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-07-20 | — | — | US | disclosed |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | SONIC MASTER LIMITED (VG) | 2020-10-22 | — | — | US | disclosed |
| EP-1656372-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2013-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | SYK 7/4885EGFR 637/4885JAK1 297/4885 |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | SYK 7/4885EGFR 637/4885JAK1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.